Tramadol is a centrally acting synthetic analgesic. Recently, tramadol overdose has become one of the most common causes of acute poisoning in Egypt and worldwide. Common symptoms of toxicity include respiratory depression and seizure. Hypoglycemia is another potentially fatal hazard that is newly emerging in association with tramadol. Therefore, the aim of this study is to investigate the effect of tramadol poisoning on blood glucose level and whether or not this effect is associated with tramadol-induced acute pancreatitis. Methods: A prospective study was conducted on patients admitted to the Poison Control Center, Ain Shams University hospitals from November 2014 to August 2016 with acute tramadol poisoning. All the patients were subjected to complete medical history, physical examination and routine biochemical laboratory tests. In addition to, measurement of serum levels of amylase, lipase and insulin. Blood glucose level was obtained twice; on admission and on the second day. Results: twenty nine patients, 25 males (86.2%) and 4 females (13.79%) met inclusion criteria. Mean age was (31.34 ± 8.75 years). There was significant decrease of blood pressure and respiratory rate in the tramadol poisoned patients (case group) as compared with the control group. The most frequent manifestations were; nausea and vomiting (93.1%), abdominal pain (86.2%), coma II (55.17%), miosis (37.93%) and sweating (34.48%). There was significant decrease of pH, PO2 and HCO3 and a significant increase of PCO2 in tramadol intoxicated patients. The case group showed significant decrease of glucose level on the second day as compared to the control group, as well as, when compared with glucose level on admission day. There was a significant increase of serum amylase level and a non-significant change of serum lipase and insulin levels among the case group in comparison with the control group.
INTRODUCTION
Tramadol is a centrally acting synthetic analgesic agent with opioid and non-opioid properties (Fournier et al., 2015) . It is used for moderate to severe pain relief due to its relatively lower risk of physical dependence and respiratory depression and better safety profile in comparison with other opiates (Ghamsari et al., 2016) .
The mode of action of tramadol is not fully understood, but two acceptable complementary mechanisms are; binding to µ opioid receptors and inhibition of norepinephrine and serotonin reuptake (Mugunthan and Davoren, 2012; Beakley et al., 2015).
Tramadol is available, in both oral and parenteral pharmaceutical forms (Ghamsari et al., 2016). The drug is rapidly absorbed orally, a peak concentration is detected in 2-3 hours. It has extensive tissue distribution. Its volume of distribution is about 3 L/kg. Thirty per cent of tramadol is excreted unchanged renally, while the remaining is metabolized in liver by N-and Odemethylation and catalyzed by cytochrome P450 (CYP2D6) to many metabolites. The active metabolite (M1) shows higher affinity for the µ opioid receptors and has twice the potency of the parent drug The objective of this study is to investigate the effect of tramadol poisoning on blood glucose level and whether or not this effect is associated with tramadol-induced acute pancreatitis in patients admitted to Poison Control Center of Ain Shams University Hospitals (PCC-ASUH).
PATIENTS & METHODS
A prospective observational study was conducted in PCC-ASUH during the period between November 2014 and August 2016. Adult patients (≥18 year-old) with acute tramadol only toxicity based upon history and clinical presentation were selected, in addition to healthy volunteers of matched age and gender who served as a control group. Exclusion criteria included any patient with history of neurological, cardiovascular, pulmonary, liver, renal or pancreatic and other endocrinal diseases. Exclusion criteria included also diabetics, pregnants and any patient with co-ingestion of other opioids, cannabis, anti-psychotic, antiepileptic, anti-depressant, 
RESULTS
Twenty nine patients, 25 males (86.2%) and 4 females (13.79%) met inclusion criteria. Mean age was (31.34 ± 8.75 years). Patients of tramadol abuse intake were (26; 89.65%) while those with suicidal intake were (3; 10.34%) and none showed accidental intake. Oral (tablets) route of intake was in (23; 79.31%) and injection route was in (6; 20.68%). The exact amount of tramadol intake could not be identified. The average delay time was (3.7± 2.6 hours) ranging between (1-12 hours).
Table (1): shows that there was a significant decrease of systolic and diastolic blood pressure and respiratory rate in tramadol toxicity patients in comparison to the control. While, there was non-significant change between tramadol toxicity patients and the control group as regard the heart rate and temperature.
Table (2): shows the average values of admission day clinical data of tramadol toxicity patients in which sweating was manifested in 10 patients (34.48%), cold clammy skin in 6 patients (20.68%). Eleven patients (37.93%) showed reactive miosis and 4 patients (6.89%) showed mydriasis. Most patients (16; 55.17%) presented with coma II and 7 patients (24.13%) experienced seizure. Cyanosis was obvious in 3 patients (10.34%), seven patients (24.13%) were with respiratory distress, while 2 patients (6.89%) had acute pulmonary edema and 2 patients (6.89%) were with apnea. Nine patients (31.03%) needed ICU admission and mechanical ventilation.
Regarding gastrointestinal manifestations; nausea and vomiting were the most common symptoms (27 patients; 93.1%) followed by abdominal pain (25 patients; 86.2%). Table ( 3): reveals that serum levels of Na+, k+, creatinine, urea, ALT, AST and HbA1c showed non-significant change between tramadol poisoned patients and the control group.
Table (4): shows that there was highly significant decrease of pH and PO 2 and a highly significant increase of PCO 2 in tramadol overdose patients as compared with the control group. Also, there was a significant decrease of HCO 3 in tramadol overdose patients in comparison with the control group. Table (5): reveals that there was non-significant change between tramadol poisoned patients and the control group regarding blood glucose level on admission day (first day). On the other hand, there was a significant decrease of glucose level on the second day as compared to the control, as well as, when compared with glucose level on the first day. The glucose level ranged between (50-213 mg/dL) on admission and on the second day the level ranged between (50-131mg/dL). Regarding blood glucose level in this study, there was non-significant difference of admission (first day) blood glucose level as compared with the control, while there was significant decrease of blood glucose level on the second day as compared with the control as well as when compared with the first day level. Hypoglycemic patients in this study comprised (17.24%) on first day and (48.27%) on second day. Other previous studies reported two cases of tramadol-induced hypoglycemia; one in an 88-year-old woman without diabetes and the other in an 8-year-old girl with diabetes. In both cases, the hypoglycemia resolved spontaneously after discontinuation of tramadol (Grandvuillemin et al. (2015) fourteen patients (11%) experienced hypoglycemia in tramadol overdose patients. They found nonsignificant relation between the dose of tramadol and blood glucose level.
The risk of hypoglycemia with tramadol is not well described (Fournier et al., 2015) . Tramadol is metabolized in the liver to its active metabolites. The active metabolite (M1) has more affinity (200 times) for the μ opioid receptors and also it has more inhibitory effect on biogenic amine reuptake than that of parent drug molecule analgesic drug reported to cause hypoglycemia is propoxyphene (Taugourdeau et al., 2011) . Tramadolinduced hypoglycemia is related to its pharmaco-dynamic properties. Tramadol mainly acts through two mechanisms; the activation of µ opioid receptors and the inhibition of central serotonin and norepinephrine reuptake (Bourne et al., 2013; Beakley et al.,  2015) . Tramadol activation of µ opioid receptors may increase the risk of hypoglycemia.
In rats with streptozotocin-induced diabetes, a tramadol injection dose-dependent glucose-lowering effect was observed and this effect was blocked in rats pretreated with naloxone, suggesting a strong implication of the µ pathways in tramadol directly reducing hepatic gluconeogenesis and enhancing peripheral glucose utilization and glucose uptake into skeletal muscle via non-insulin-mediated mechanisms (Cheng et al., 2001 ). The same authors had also shown that μ opioid receptors stimulation lowered plasma glucose in normal and diabetic rats and that loperamide, another μ receptor agonist, exerted the same effect as tramadol (Tzeng et al., 2003) . In a different animal model, tramadol-mediated stimulation of µ receptors in the cerebral cortex and hypothalamus appeared to increase insulin signaling, thereby increasing hepatic sensitivity to insulin without affecting hepatic glucose output directly (Choi et al.,  2005) .
In addition, serotonin pathways are also known to have complex effects on peripheral glucose homeostasis (El Merahbi et al., 2015) . In rat models of diabetes, serotonin induced β endorphin release and stimulated muscle glucose utilization through the activation of μ opioid receptors by a mechanism, which is neither dose-nor insulin dependent (Chi et al., 2007) 
